Jame Abraham, MD, FACP, on HER2-Positive Metastatic Breast Cancer: Choosing a Regimen in Clinical Practice

February 04, 2026 By The ASCO Post Staff

Jame Abraham, MD, FACP, puts findings from several trials in HER2-positive breast cancer into context, including HER2CLIMB, which investigated tucatinib, trastuzumab, and capecitabine in pretreated patients with metastatic disease; DESTINY Breast-09, which evaluated fam-trastuzumab deruxtecan-nki (T-DXd) plus pertuzumab in patients with advanced or metastatic disease who had received no previous chemotherapy or HER2-directed therapy for metastatic disease; and PATINA, which looked at the addition of palbociclib to maintenance anti-HER2 and endocrine therapies in hormone receptor–positive disease. Dr. Abraham is Enterprise Chair of the Department of Hematology & Medical Oncology at Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine.

Related Content